SCHEMBL5137312

SCHEMBL5137312

CCCCn1c(-c2ccccc2)nc(-c2ccccc2)c1CN(CC)Cc1ccc(CC)cc1

nearest known ligand 0.48

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.48
TSHR P16473 5/20 0.45
ALDH1A1 P00352 6/20 0.40
KDM4E B2RXH2 5/20 0.40
HPGD P15428 5/20 0.40
HSD17B10 Q99714 5/20 0.40
CYP3A4 P08684 4/20 0.40
HSD11B1 P28845 2/20 0.39
NR1H3 Q13133 1/20 0.38
HDAC1 Q13547 1/20 0.37
PDE4B Q07343 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5134746 0.94 C5AR1 (0.48) C5AR1TSHRALDH1A1KDM4EHPGD
SCHEMBL5137883 0.94 TSHR (0.48) C5AR1TSHRALDH1A1KDM4EHPGD
SCHEMBL5135643 0.93 C5AR1 (0.48) C5AR1TSHRALDH1A1KDM4EHPGD
SCHEMBL5135106 0.92 C5AR1 (0.47) C5AR1TSHRALDH1A1KDM4EHPGD
SCHEMBL5072249 0.92 C5AR1 (0.47) C5AR1TSHRALDH1A1KDM4EHPGD
SCHEMBL5134971 0.91 C5AR1 (0.46) C5AR1TSHRALDH1A1KDM4EHPGD
SCHEMBL5072228 0.91 C5AR1 (0.46) C5AR1TSHRALDH1A1KDM4EHPGD
SCHEMBL651094 0.90 TSHR (0.50) C5AR1TSHRALDH1A1KDM4EHPGD
SCHEMBL5136301 0.89 CASR (0.45) C5AR1TSHRALDH1A1KDM4EHPGD
SCHEMBL5135994 0.89 KDM4E (0.48) C5AR1TSHRALDH1A1KDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed